Actively Recruiting
Peripheral Serotonin and Albinism
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2025-09-12
160
Participants Needed
1
Research Sites
103 weeks
Total Duration
On this page
Sponsors
A
Assistance Publique - Hôpitaux de Paris
Lead Sponsor
U
URC-CIC Paris Descartes Necker Cochin
Collaborating Sponsor
AI-Summary
What this Trial Is About
Serotonin (5-HT or 5-hydroxytryptamine) is a monoamine primarily known for its role as a neurotransmitter in the central nervous system (CNS). However, the functions of serotonin go beyond its role in the central nervous system: different peripheral tissues have the capacity to produce and/or use serotonin locally, forming systems called "micro-serotonergic" systems. Among the peripheral roles of serotonin, previous work by the Iron and Immunity team, INSERM U1016, Institut Cochin (Paris), was able to show that serotonin has a positive role on erythropoiesis and the survival of red blood cells, and the team's ongoing work suggests that serotonin also impacts iron metabolism. In humans and in mouse models, several studies have suggested a role for serotonin in pigmentation. In certain syndromic forms of albinism such as Hermansky Pudlak syndrome, platelet serotonin levels are reduced in connection with a decrease in dense platelet granules (delta granules): this characteristic is even part of the diagnostic criteria. Preliminary data from the Iron and Immunity team found: * Changes in serotonin levels in children with albinism compared to control patients, * Changes in hemoglobin level and mean corpuscular volume (MCV) in children with albinism (towards anemia and microcytosis), * Changes in the iron balance in children with albinism (towards iron deficiency). The hypothesis of this research is that peripheral serotonin plays a role in the clinical and biological manifestations of oculocutaneous albinism.
CONDITIONS
Official Title
Peripheral Serotonin and Albinism
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with albinism aged 2 to 17 years
- Followed in the MAGEC-Necker reference center during the inclusion period
- Informed consent obtained from parental authority holders and patients of understanding age
- Control patients aged 2 to 17 years who consulted at Necker hospital emergency or surgical services during the inclusion period
- Control patients with normal complete blood count
- Control patients with normal C-reactive protein test
- No opposition from parental authority holders within one month after sending the study information note
You will not qualify if you...
- Inability to have a blood test for patients
- Abnormal blood count for control patients
- Elevated C-reactive protein above laboratory standard for control patients
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hôpital Necker-Enfants Malades
Paris, France, 75015
Actively Recruiting
Research Team
S
Smail HADJ-RABIA, MD, PhD
CONTACT
H
Hélène Morel
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here